# Angiodynamics Inc: Form 10-Q for the period ended Feb 28, 2014

- Company: [Angiodynamics Inc](/companies/ango.md) (CIK 1275187)
- Form: 10-Q
- Filed: 2014-04-09
- Accepted by EDGAR: Apr 9, 2014, 16:23 ET
- Period: 2014-02-28
- Accession: 0001193125-14-137100
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1275187/000119312514137100/d687110d10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1275187/000119312514137100/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2014-02-28.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2013-12-06 to 2014-02-28 | $88.2m | us-gaap:SalesRevenueNet |
| Revenue | 9 months, 2013-06-01 to 2014-02-28 | $260.4m | us-gaap:SalesRevenueNet |
| Cost of revenue | 3 months, 2013-12-06 to 2014-02-28 | $42.6m | us-gaap:CostOfGoodsSold |
| Cost of revenue | 9 months, 2013-06-01 to 2014-02-28 | $127.3m | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months, 2013-12-06 to 2014-02-28 | $45.6m | us-gaap:GrossProfit |
| Gross profit | 9 months, 2013-06-01 to 2014-02-28 | $133.0m | us-gaap:GrossProfit |
| Research and development | 3 months, 2013-12-06 to 2014-02-28 | $7.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months, 2013-06-01 to 2014-02-28 | $20.8m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months, 2013-12-06 to 2014-02-28 | $7.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2013-06-01 to 2014-02-28 | $10.4m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2013-12-06 to 2014-02-28 | $917.0k | us-gaap:InterestExpense |
| Interest expense | 9 months, 2013-06-01 to 2014-02-28 | $3.1m | us-gaap:InterestExpense |
| Income tax | 3 months, 2013-12-06 to 2014-02-28 | $476.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2013-06-01 to 2014-02-28 | $268.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2013-12-06 to 2014-02-28 | $5.1m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2013-06-01 to 2014-02-28 | $4.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2013-12-06 to 2014-02-28 | $0.14 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2013-06-01 to 2014-02-28 | $0.13 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2013-12-06 to 2014-02-28 | $0.15 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2013-06-01 to 2014-02-28 | $0.13 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2013-12-06 to 2014-02-28 | 35,704,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2013-06-01 to 2014-02-28 | 35,372,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Capital expenditure | 9 months, 2013-06-01 to 2014-02-28 | $9.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2014-02-28 | $7.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2014-02-28 | $140.1m | us-gaap:AssetsCurrent |
| Total assets | at 2014-02-28 | $792.2m | us-gaap:Assets |
| Current liabilities | at 2014-02-28 | $63.4m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2014-02-28 | $254.5m | us-gaap:Liabilities |
| Current portion of debt | at 2014-02-28 | $5.0m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | at 2014-02-28 | $537.7m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 26,960 characters.

The following information should be read together with the consolidated financial statements and the notes thereto and other information included elsewhere in this quarterly report on Form 10-Q.

### Forward-Looking Statements

This quarterly report on Form 10-Q, including the sections entitled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” or variations of such words and similar expressions, are forward-looking statements. These forward looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from our expectations. Factors that may affect our actual results achieved include, without limitation, our ability to develop existing and new products, future actions by FDA or other regulatory agencies, results of pending or future clinical trials, the results of ongoing litigation, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, as well as our ability to integrate purchased businesses. Other risks and uncertainties include, but are not limited to, the factors described from time to time in our reports filed with the SEC, including our Form 10-K for the fiscal year ended May 31, 2013.

Although we believe that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate and, therefore, there can be no assurance that the forward-looking statements included in this quarterly report on Form 10-Q will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by us or any other person that our objectives and plans will be achieved. Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, speak only as of the date made. AngioDynamics disclaims any obligation to update the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date stated, or if no date is stated, as of the date of this document.

### Overview

We design, manufacture and sell a wide range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Our devices are generally used in minimally invasive, image-guided procedures. Most of our products are intended to be used once and then discarded, or they may be temporarily implanted for short- or long-term use.

We sell our products in the United States through a direct sales force and outside the U.S. through a combination of direct sales and distributor relationships. For both the three and nine months ended February 28, 2014 and 2013, approximately 19% of our net sales were from markets outside the United States.

Our growth depends, in part, on the introduction of new and innovative products, together with ongoing enhancements to our existing products, through internal product development, technology licensing and strategic alliances. We recognize the importance of, and intend to continue to make investments in, research and development. For the three and nine months ended February 28, 2014, our research and development (“R&D”) expenditures were $7.0 million and $20.8 million, respectively, which represented 8% of net sales. Comparable prior year expenditures for R&D were $5.8 million and $19.9 million, respectively, which represented 7% and 8%, respectively, of net sales for those periods. We expect to continue to spend considerable amounts on R&D activities in the future; however, downturns in our business could cause us to reduce our R&D spending.

Except to the extent we can further use our cash and short term investments or our equity securities as acquisition capital, we will require additional equity or debt financing to fund any future significant acquisitions.

Our ability to further increase our profitability will depend in part on improving gross profit margins. Factors such as changes in our product mix, new technologies and price pressures may cause our margins to grow at a slower rate than we have anticipated, or to decline. We are currently operating our manufacturing facilities at less than full capacity but within our historical normal capacity levels.

### Recent Developments

See Note A to our consolidated financial statements in this Quarterly Report on Form 10-Q for recent developments.

### New Accounting Pronouncements

Information regarding new accounting pronouncements is included in Note M to our consolidated financial statements in this Quarterly Report on Form 10-Q.

### Medical Device Excise Tax

A Medical Device Excise Tax (MDET) was enacted into law as part of the Health Care Education Reconciliation Act of 2010 and imposes an excise tax on medical device manufacturers on their sales in the U.S of certain devices after December 31, 2012. The tax is 2.3% of the taxable base which is generally defined as 75% of the selling price of the taxable product. For the three and nine months ended February 28, 2014, we incurred $1 million and $3 million, respectively, related to MDET which is recorded in the Consolidated Statements of Income as an operating expense under the caption “Medical device excise tax”.

### Results of Operations for the Three Months ended February 28, 2014 and February 28, 2013

For the three months ended February 28, 2014, we reported a net income of $5.1 million, or $0.14 per diluted share, on net sales of $88.2 million, compared with a net loss of $1 million, or $(0.03) per share, on net sales of $81.6 million during the same quarter of the prior year.

The table below presents certain operating data as a percentage of net sales:

|  | Three Months Ended Feb 28, 2014 | Feb 28, 2013 |
| --- | ---: | ---: |
| Net sales | 100.0% | 100.0% |
| Gross profit | 51.7% | 50.5% |
| Research and development | 8.0% | 7.1% |
| Sales and marketing | 23.5% | 22.7% |
| General and administrative | 7.1% | 7.4% |
| Amortization of intangibles | 4.8% | 5.3% |
| Change in fair value of contingent consideration | (4.7%) | 0.8% |
| Acquisition, restructuring and other items, net | 3.4% | 6.3% |
| Medical device excise tax | 1.1% | 0.8% |
| Operating income | 8.6% | 0.1% |
| Other income (expenses) | (2.3%) | (2.3%) |
| Income taxes | 0.5% | (1.0%) |
| Net income (loss) | 5.8% | (1.2%) |

Net sales - Net sales are derived from the sale of our products and related freight charges, less discounts and returns. For the three months ended February 28, 2014, net sales increased $6.6 million to $88.2 million when compared to the same period in the prior year. This increase was primarily attributable to increased sales of EVLT procedure kits, sales of the recently introduced AngioVac product line and increased microwave product sales, partially offset by decreased sales of RFA, and products sold through our supply agreement arrangement.

From a product line perspective, Peripheral Vascular sales increased $4.8 million or 11% from the prior year period to $47.4 million. This increase was primarily attributable to increased sales of EVLT procedure kits and sales of the recently introduced AngioVac product line. Vascular Access sales were $27.2 million, an increase of $0.9 million from the prior year period. This increase is attributable to increased sales of our PICC and port products. Oncology/Surgery sales were $12.0 million, an increase of 15% from prior year sales of $10.0 million, primarily due to increased sales of our microwave and NanoKnife products.

From a geographic perspective, U.S. sales increased $6.1 million or 10% during the third quarter of fiscal 2014 to $69.9 million when compared to the same period in the prior year. This increase was primarily attributable to increased sales of EVLT procedure kits, sales of the recently introduced AngioVac product line and increased microwave and NanoKnife product sales. International sales were $16.8 million in the fiscal third quarter of 2014, an increase of 7% from $15.7 million in the comparable prior year period.

The increase is attributable to increased sales of PICCs, Microwave and NanoKnife products, offset by decreases in RFA and Venous products. Our supply agreement arrangement, which we do not include in either the U.S. or International geographic sales, declined 26% to $1.6 million from $2.1 million.

Gross profit - Gross profit consists of net sales less the cost of goods sold, which includes the costs of materials, products purchased from third parties and sold by us, manufacturing personnel, royalties, freight, business insurance, depreciation of property and equipment and other manufacturing overhead. Our gross profit as a percentage of sales increased from 50.5% to 51.7% during the period. The increase is largely attributable to improved operating efficiencies and mix of products sold.

Research and development expenses - Research and development (“R&D”) expenses include costs to develop new products, enhance existing products, validate new and enhanced products, manage clinical, regulatory and medical affairs and our intellectual property. For the three months ended February 28, 2014, R&D expenses increased $1.3 million to $7 million. As a percentage of net sales, R&D expenses were 8.0% and 7.1% for the third quarters of 2014 and 2013, respectively.

Sales and marketing expenses - Sales and marketing (“S&M”) expenses consist primarily of salaries, commissions, travel and related business expenses, attendance at medical society meetings, product promotions and marketing activities. S&M expenses increased $2.2 million or 12% to $20.7 million when compared to the same period in the prior year. The increase is primarily attributable to the expansion of the US and International sales forces to support the product lines and growth initiatives and increased commissions based on increased U.S. sales. Also contributing to the increase in S&M expenses is the addition of AngioVac clinical specialists to support this product line. As a percentage of net sales, S&M expenses increased to 23.5% in the fiscal first quarter of 2014, from 22.7% for the same prior year period.

General and administrative expenses - General and administrative (“G&A”) expenses include executive management, finance and accounting, information technology, human resources, business development, legal, and the administrative and professional costs associated with those activities. G&A expenses increased $0.2 million, or 3%, to $6.2 million when compared to the same period in the prior year. G&A expenses decreased to 7.1% of net sales from 7.4% in the prior year period.

Amortization of intangibles - Amortization of intangibles decreased $0.1 million to $4.2 million during the period, primarily due to the write-off of intangibles in the prior year related to our Benephit product line.

Change in fair value of contingent consideration - The third quarter of fiscal 2014 included a benefit of $5.0 million consisting of a revaluation of the Vortex contingent consideration based on a revised sales forecast. This was partially offset by the normal expense of $0.8 million related to the change in fair value of the contingent consideration associated with the Vortex, Microsulis and Clinical Devices acquisitions.

Acquisition, restructuring and other items, net - The third quarter of fiscal 2014 included Acquisition, restructuring and other items, net expenses of $3.0 million which primarily consisted of $1.3 million of transaction and severance expenses related to the acquisitions and integration of Navilyst and $1.0 million of costs related to our NY plant consolidation program. The prior year total of $5.2 million which primarily consisted of $1.3 million of transaction and severance expenses related to the acquisition of Navilyst, $1.6 million write off of the Benephit product line, $1.0 million of litigation costs and approximately $0.8 million for expenses related to the closure of our manufacturing facility in the UK and other business development projects.

Medical device excise tax - The third quarter of fiscal 2014 included $1 million of expense attributed to Medical Device Excise Tax enacted into law effective January 1, 2013.

Operating income - During the three months ended February 28, 2014, operating income increased $7.5 million to $7.6 million. As a percentage of sales, operating income was 8.6% and 0.1% for the three months ended February 28, 2014 and 2013, respectively.

Other expenses - Other expenses for the three months ended February 28, 2014 increased $0.1 million to $2 million when compared to the same period in the prior year.

Income taxes - Our effective tax rate was a 9% expense for the third fiscal quarter of 2014 compared with a 46% benefit on the prior year period loss. The current quarter expense reflects the benefit of the $5.0 million nontaxable adjustment to the contingent liability related to Vortex Medical, Inc., a seven month benefit from the R&D tax credit that expired on December 31, 2013 and a benefit from lower tax rates in foreign jurisdictions in which we operate, offset by non-deductible interest expense related to contingent payments and true-ups of our fiscal year 2013 US income tax returns. As mentioned last fiscal quarter, our ASC 718 APIC pool, which has been historically reduced when share-based compensation cost previously recognized by us was greater than the deduction allowed for income tax purposes based on the price of our common stock on the date of exercise or vesting, is fully depleted. This depletion resulted in a discrete tax expense in the third quarter of 2014. The prior year period reflected the magnified impact of non-deductible items caused by reduced taxable income net of the tax benefits related to the retroactive renewal of the R&D tax credit that had previously expired on December 31, 2011 and was retroactively reinstated during fiscal year 2013.

Net income (loss) - For the three months ended February 28, 2014, we reported net income of $5.1 million, compared to a net loss of $1.0 million for the same period in the prior year.

### Results of Operations for the Nine Months ended February 28, 2014 and February 28, 2013

For the nine months ended February 28, 2014, we reported net income of $4.6 million, or $0.13 per diluted share, on net sales of $260.4 million, compared with net income of $0.3 million, or $0.01 per share, on net sales of $252 million during the same period in the prior year.

The following table sets forth certain operating data as a percentage of net sales:

|  | Nine Months Ended Feb 28, 2014 | Feb 28, 2013 |
| --- | ---: | ---: |
| Net sales | 100.0% | 100.0% |
| Gross profit | 51.1% | 49.5% |
| Research and development | 8.0% | 7.9% |
| Sales and marketing | 23.7% | 22.1% |
| General and administrative | 7.3% | 7.9% |
| Amortization of intangibles | 4.9% | 4.7% |
| Change in fair value of contingent consideration | (1.0%) | 0.3% |
| Acquisition, restructuring and other items, net | 3.0% | 3.9% |
| Medical device excise tax | 1.1% | 0.3% |
| Operating income | 4.0% | 2.3% |
| Other income(expenses) | (2.1%) | (2.3%) |
| Income taxes | 0.1% | (0.0%) |
| Net income (loss) | 1.8% | 0.1% |

Net sales - During the nine months ended February 28, 2014, net sales increased $8.4 million to $260 million when compared to the same period in the prior year. This increase was primarily attributable to increased sales of EVLT procedure kits, sales of the recently introduced AngioVac product line and increased microwave product sales, partially offset by decreased sales of RFA and Habib devices, and products sold through our supply agreement arrangement.

From a product line perspective, Peripheral Vascular sales increased $10.0 million or 8% from the prior year period to $141.7 million. This increase was primarily attributable to increased sales of EVLT procedure kits and sales of the recently introduced AngioVac product line. Vascular Access sales were $78.1 million, a decrease of $1.6 million or 2% from the prior year period. This decrease is attributable to lower sales of PICC and Dialysis products. Oncology/Surgery sales were $35.7 million, an increase of 6% from prior year sales of $33.7 million, primarily due to increased sales of our microwave product partially offset by the decrease in RFA and Habib devices.

From a geographic perspective, U.S. sales increased $9.8 million or 5% to $206.5 million when compared to the same period in the prior year. This increase was primarily attributable to increased sales of EVLT procedure kits, sales of the recently introduced AngioVac product line and increased microwave product sales, partially offset by decreased sales of PICCs, RFA and Habib devices. International sales were $49.1 million in the first nine months of fiscal 2014, an increase of 1% from $48.4 million in the comparable prior year period. The decrease is attributable to lower sales of RFA and Habib devices, EVLT and port products, partially offset by increased PICC sales. Our supply agreement arrangement, which we do not include in either the U.S. or International geographic sales, declined 30% to $4.8 million from $6.9 million.

Gross profit - As a percentage of sales, gross profit increased from 49.5% to 51.1% when compared to the same period in the prior year. The increase is due to $3.8 million of step-up basis amortization related to Navilyst inventory acquired in the prior year and improved operational efficiencies

Research and development expenses - R&D expenses increased by 4%, to $20.8 million during the nine months ended February 28, 2014. The increase is primarily due to a increased R&D spending on clinical trials and other new product development.

Sales and marketing expenses - S&M expenses increased $6 million or 11% to $61.7 million during the nine months ended February 28, 2014, primarily attributable to the expansion of the US and International sales forces to support the product lines and growth initiatives. Also contributing to the increase in S&M expenses is the addition of AngioVac clinical specialists to support this product line and a return to higher U.S. sales staffing levels. As a percentage of net sales, S&M expenses increased to 23.7 from 22.1% when compared to the same period in the prior year.

General and administrative expenses - G&A expenses decreased $0.8 million, or 4%, to $19.1 million when compared to the same period in the prior year primarily due to cost reduction programs following the Navilyst acquisition. G&A expenses decreased to 7.3% of net sales from 7.9% in the prior year period.

Amortization of intangibles - For the nine months ended February 28, 2014, amortization of intangibles increased $0.9 million to $12.9 million when compared to the same period in the prior year. The increase is primarily due to the amortization of intangibles acquired in the Vortex and Microsulis acquisitions. As a percentage of sales, amortization increased from 4.7% to 4.9% during the period.

Acquisition, restructuring and other items, net - The first nine months of fiscal 2014 included Acquisition, restructuring and other items, net expenses of $7.7 million which primarily consisted of $4.1 million of transaction and severance costs related to the Navilyst acquisition and integration, $1.0 million of costs related to the NY plant consolidation program, $0.7 million of costs related to other recent acquisitions and $1.1 million of litigation costs. The prior year period expense of $9.9 million which primarily consisted of $5.2 million of transaction and severance costs related to the acquisition of Navilyst, $1.6 million for expenses related to the closure of our manufacturing facility in the UK, a $1.6 million loss related to the write off the Benephit product line, $0.8 million of transaction costs related to the acquisition of Vortex and Microsulis, $1.3 million of litigation costs, partially offset by the $0.7 million net gain on the sale of our PDT laser product line.

Operating income - For the nine months ended February 28, 2014, operating income increased $4.6 million to $10.4 million when compared to the same period in the prior year. As a percentage of sales, operating income increased to 4% from 2.3% during the period.

Other expenses - Other expenses for the nine months ended February 28, 2014, decreased $0.1 million to $5.6 million when compared to the same period in the prior year. The decrease is due to a $0.9 million reduction in interest expense as a result of our recent debt refinancing but was offset by increases in other expenses.

Income taxes - Our effective tax rate was a 6% expense for the first nine months of fiscal 2014 compared with 63% benefit on the prior year period loss. The current period reflects the benefit of the $5.0 million nontaxable contingent liability adjustment related to the acquisition of Vortex Medical, Inc., a seven month benefit from the R&D tax credit that expired on December 31, 2013 and a benefit from lower tax rates in foreign jurisdictions in which we operate, offset by non-deductible expense related to contingent payments and true-ups of our fiscal year 2013 US income tax returns. Additionally during the 2014 period, our ASC 718 APIC pool, which has been historically reduced when share-based compensation cost previously recognized by us was greater than the deduction allowed for income tax purposes based on the price of our common stock on the date of exercise or vesting, became fully depleted. The prior year period was impacted by a magnified impact of non-deductible items caused by reduced taxable income in fiscal 2013, non-deductible costs related to the acquisition of Vortex net of tax benefits related to the retroactive renewal of the R&D credit that had previously expired on December 31, 2011 and was retroactively reinstated during fiscal year 2013.

Net income (loss) - For the nine months ended February 28, 2014, we reported net income of $4.6 million, an increase of $4.3 million when compared to the same period in the prior year.

### Liquidity and Capital Resources

Our cash and cash equivalents totaled $7.4 million as of February 28, 2014, compared with $21.8 million as of May 31, 2013. Marketable securities totaled $1.8 million and $2.2 million as of February 28, 2014 and May 31, 2013, respectively, and consist of U.S. government issued or guaranteed securities, corporate bonds and auction rate securities. As of February 28, 2014, total debt was $139 million primarily comprised of short and long-term bank debt that financed our acquisition of Navilyst in May 2012 which was refinanced in September 2013. In accounting for the Vortex, Microsulis and Clinical Devices acquisitions, the fair value of contingent milestone payments was remeasured as of February 28, 2014. As a result, $55.8 million was reflected in “Contingent consideration, net of current portion” and $12.2 million was reflected in “Current portion of contingent consideration” on the consolidated balance sheet.

The table below summarizes our cash flows for the nine months ended February 28, 2014 and 2013 (in thousands of dollars):

| Cash provided by (used in): | Nine Months Ended Feb 28, 2014 | Feb 28, 2013 |
| --- | ---: | ---: |
| Operating activities | $15,174 | $15,515 |
| Investing activities | (13,024) | (17,826) |
| Financing activities | (16,656) | (4,529) |
| Effect of exchange rate changes on cash and cash equivalents | 86 | (43) |
| Net change in cash and cash equivalents | $(14,420) | $(6,883) |

Net cash provided by operating activities during the nine months ended February 28, 2014 and 2013 was $15.2 million and $15.5 million, respectively. Cash provided by operating activities during the nine months ended February 28, 2014, was primarily the result of non-cash expense items, such as amortization and depreciation, partially offset by changes in the fair value of contingent consideration and increases in inventories and accounts receivable. The prior year period consisted of similar items with a larger prior year change in working capital due to larger increased inventories coupled with a reduction in accounts payable and accrued liabilities.

Net cash used in investing activities during the nine months ended February 28, 2014 and 2013 was $13.0 million and $17.8 million, respectively. The net cash used in investing activities for the current year period consisted primarily of fixed asset additions and the acquisition of Clinical Devices, partially offset by net proceeds from the sale of marketable securities. The prior year period use of cash consisted primarily of the Vortex acquisition, partially offset by net proceeds from the sales of marketable securities and the sale of our PDT laser product line.

Net cash used in financing activities during the nine months ended February 28, 2014 and 2013 was $16.7 million and $4.5 million, respectively. The current year period consisted primarily of the payment of contingent consideration related to the acquisition of Vortex and the refinancing of long-term debt, partially offset by proceeds from the exercise of stock options and purchases related to our Employee Stock Option plan. The repayment of long-term debt was the primary source of the prior year period use of cash.

Our contractual obligations and their effect on liquidity and cash flows have not changed substantially, other than the restructuring of our long term debt as discussed above and in Note F, from that disclosed in our Annual Report on Form 10-K for our fiscal year ended May 31, 2013.

We believe that our current cash and investment balances, together with cash generated from operations and our remaining revolving credit facility capacity of $58.6 million as of February 28, 2014, will provide sufficient liquidity to meet our anticipated needs for capital for at least the next 12 months. If we seek to make significant acquisitions of other businesses or technologies in the future for cash, we may require external financing.

## Market risk

As filed, 6,777 characters.

We are exposed to market risk from changes in interest rates on investments and financing that could impact our results of operations and financial position. Although we have entered into interest rate swaps with a bank to limit our exposure to interest rate change on our variable interest rate financings, we do not currently engage in any other hedging or market risk management tools.

#### New Credit Agreement

On September 19, 2013, we entered into a Credit Agreement (the “Credit Agreement”) with the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A. and Keybank National Association as co-syndication agents, and J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Keybank National Association as joint bookrunners and joint lead arrangers.

The Credit Agreement provides for a $100 million senior secured term loan facility (“Term Loan”) and a $100 million senior secured revolving credit facility, which includes up to a $20 million sublimit for letters of credit and a $5 million sublimit for swingline loans (the “Revolving Facility”, and together with the Term Loan, the “Facilities”).

The proceeds of the Term Loan and a portion of the proceeds of the Revolving Facility were used to repay our Credit Agreement (the “Existing Credit Agreement”) dated as of May 22, 2012 with the lenders party thereto, JPMorgan Chase Bank, N.A., as administrative agent, Bank of America, N.A. and Keybank National Association as co-syndication agents, and J.P. Morgan Securities LLC, Merrill Lynch, Pierce, Fenner & Smith Incorporated and Keybank National Association as joint bookrunners and joint lead arrangers.

The proceeds of the Revolving Facility may be used for general corporate purposes of AngioDynamics and its subsidiaries. The Facilities have a five year maturity. The Term Loan has a quarterly repayment schedule equal to 5%, 5%, 10%, 15% and 65% of its principal amount in years one through five, respectively. Interest on both the Term Loan and Revolving Facility will be based on a base rate or Eurodollar rate plus an applicable margin which increases as our total leverage ratio increases, and with the base rate and Eurodollar rate having ranges of 0.50% to 1.25% and 1.50% to 2.25% respectively. After default, the interest rate may be increased by 2.0%. The Revolving Facility will also carry a commitment fee of 0.20% to 0.35% per annum on the unused portion.

Our obligations under the Facilities are unconditionally guaranteed, jointly and severally, by our material direct and indirect domestic subsidiaries (the “Guarantors”). All obligations of AngioDynamics and the Guarantors under the Facilities are secured by first priority security interests in substantially all of the assets of AngioDynamics and the Guarantors.

In June 2012, we entered in an interest rate swap agreement (the “Swap Agreement”), with an initial notional amount of $100 million, to limit the effect of rising of interest rates. The Swap Agreement, which qualified for hedge accounting under authoritative guidance, was a contract to exchange floating interest rate payments for fixed interest rate payments on the outstanding balance of the loan over the life of the agreement without the exchange of the underlying notional amounts. The Swap Agreement provides for a fixed rate of 0.74% above the applicable rate provided for in the Credit Agreement.

On September 19, 2013, we borrowed $100 million under the Term Facility and approximately $41.4 million under the Revolving Facility to repay the Existing Credit Agreement. As of November 30, 2013, $98.8 million and $41.4 million were outstanding under the Term Facility and Revolving Facility, respectively. The Credit Agreement includes customary representations, warranties and covenants, and acceleration, indemnity and events of default provisions, including, among other things, two financial covenants. The first financial covenant requires us to maintain, as of the end of each of our fiscal quarters, a ratio of (i) consolidated EBITDA minus consolidated capital expenditures to (ii) consolidated interest expense paid or payable in cash plus scheduled principal payments in respect of indebtedness under the Credit Agreement of not less than 1.35 to 1.00. The second financial covenant requires us to maintain, as of the end of each of our fiscal quarters, a ratio of consolidated total indebtedness to consolidated EBITDA of not greater than 3.75 to 1.00. We were in compliance with both covenants as of February 28, 2014.

On September 19, 2013, we repaid all amounts owed under the Existing Credit Agreement, and as a result, the Existing Credit Agreement was terminated. Pursuant to the terms of the Existing Credit Agreement, we had the option to repay this facility at any time prior to the maturity date without penalty.

Nearly all of our sales have historically been denominated in United States dollars. Although not significant, we transact sales in other currencies, particularly the Euro, GB pound and Canadian dollar. Approximately 6% of our sales during the nine month period ended February 28, 2014, were denominated in currencies other than the US dollar, primarily the Euro and GB pound. We currently have no significant direct foreign currency exchange risk and such risk in the future is expected to be modest.

Our excess cash is invested in highly liquid, short-term, investment grade securities with maturities primarily of less than two years. These investments are not held for speculative or trading purposes. Changes in interest rates may affect the investment income we earn on cash, cash equivalents and marketable securities and therefore affect our cash flows and results of operations. We hold investments in auction rate securities (“ARS”) in order to generate higher than typical money market investments. ARS typically are high credit quality, generally achieved with municipal bond insurance. Credit risks are eased by the historical track record of bond insurers, which back a majority of this market. Sell orders for any security traded through an auction process could exceed bids. Such instances are usually the result of a drastic deterioration of issuer credit quality. Should there be a failed auction, we may be unable to liquidate our position in the securities in the near term. We have $1.80 million in investments in two auction rate securities issued by New York state and local government authorities that have failed auctions. The authorities are current in their interest payments on the securities.

We are party to legal actions that arise in the ordinary course of business. (See Note L of Notes to Consolidated Financial Statements for more information related to legal actions.)

## Controls and procedures

As filed, 2,052 characters.

### Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, our management, under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures pursuant to Rule 13a-15(b) of the Securities Exchange Act of 1934. Based on that evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report are functioning effectively to provide reasonable assurance that the information required to be disclosed by us (including our consolidated subsidiaries) in reports filed under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and is accumulated and communicated to management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

### Changes in Internal Control over Financial Reporting

There was no change in our internal control over financial reporting in the fiscal quarter ended February 28, 2014 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

We are in the process of a multi-year implementation of a Strategic Business System project (which is our global enterprise resource planning or ERP system). In fiscal 2014, we deployed the system at our U.S. operations, the largest of our global operations and in varying degrees at our non-U.S. operations. We expect to complete the full global implementation during fiscal 2015. In response to business integration activities related to the new system, we will align and streamline the design and operation of the financial reporting controls environment to be responsive to the changing operating environment.

## Risk factors

As filed, 684 characters.

In addition to information set forth in this report, you should carefully consider the factors discussed in “Part I, Item 1A. Risk Factors” of our annual report on Form 10-K for our fiscal year ended May 31, 2013 which set forth information relating to important risks and uncertainties that could materially adversely affect our business, financial condition or operating results. You should review and consider such Risk Factors in making any investment decision with respect to our securities. An investment in our securities continues to involve a high degree of risk. There have been no material changes to the risk factors previously disclosed in our annual report on Form 10-K.

Filed Apr 9, 2014.
Source: SEC EDGAR, the filing index for accession 0001193125-14-137100. Last ingested by Listed: Nov 4, 2026, 20:24 ET. No prices; not investment advice.
